HeartFlow to Present at Morgan Stanley Global Healthcare Conference | New
REDWOOD CITY, Calif .– (BUSINESS WIRE) – Sep 1, 2021–
HeartFlow, Inc., the leader in the precision heart care revolution, today announced that the company will attend the next Morgan Stanley Global Healthcare Conference.
The management of HeartFlow Holding Inc. is scheduled to make a presentation on Wednesday, September 15 at 2:00 p.m. EST. Interested parties can access a live, archived webcast of the presentation in the “Investors” section of the Company’s website at: www.heartflow.com/investors/. A link to the company’s investor presentation is also available at www.heartflow.com/investors/.
About HeartFlow FFRct Analysis
From a standard coronary computed tomography (CTA) angiogram, HeartFlow analysis relies on deep learning and highly trained analysts to create a personalized, digital 3D model of the heart. HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and provide FFRct values along the coronary arteries. This information helps doctors assess the impact a blockage can have on blood flow and determine the optimal treatment for each patient. A positive FFRct value (≤ 0.80) indicates that a coronary blockade impairs blood flow to the heart muscle to a degree that may warrant invasive management.
Data demonstrating the safety, efficacy and cost-effectiveness of the HeartFlow assay have been published in more than 425 peer-reviewed publications, including long-term data over five years. HeartFlow analysis offers the highest diagnostic performance available from a non-invasive test. 1 To date, clinicians around the world have used HeartFlow analysis for more than 100,000 patients to aid in the diagnosis of heart disease.
HeartFlow is the leader in the revolution in precision heart care, uniquely combining human ingenuity with cutting edge technology. HeartFlow’s non-invasive HeartFlow FFRct analysis uses artificial intelligence to create a personalized three-dimensional model of the heart. Using this model, clinicians can better assess the impact of a blockage on blood flow and determine the best treatment for patients. HeartFlow’s technology reflects our roots in Silicon Valley and integrates more than two decades of scientific evidence with the latest advances in artificial intelligence. HeartFlow FFRct analysis is commercially available in the United States, United Kingdom, Canada, Europe, and Japan. For more information, visit www.heartflow.com.
- Driessen, R., et al. J Am Coll Cardiol. 2019; 73 (2), 161-73.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20210901005979/en/
CONTACT: For investors:
Leigh Salvo or Jack Droogan
[email protected] For Media:
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH CARDIOLOGY MEDICAL DEVICES
SOURCE: HeartFlow, Inc.
Copyright Business Wire 2021.
PUB: 01/09/2021 16:30 / DISC: 01/09/2021 16:30
Copyright Business Wire 2021.